体内
乙二醇
体内分布
化学
药理学
药代动力学
PEG比率
药品
纳米颗粒
材料科学
核化学
体外
纳米技术
医学
生物化学
有机化学
生物
生物技术
财务
经济
作者
Yue Huang,Chenguang Yang,Jianlin Lv,Yu Zhang,Kun Wang,Lili Ma,Zhilin Liu,Haiyang Yu,Mingqiang Li,Zhaohui Tang
标识
DOI:10.1016/j.ijpharm.2023.122849
摘要
Poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/Combretastatin A4 (CA4)/BLZ945 nanoparticles (CB-NPs) have shown great potential in synergistic cancer therapy. However, it is still unclear how the nanoparticles' formula, such as injection dose, active agent ratio, and drug loading content, affects the side effects and in vivo efficacy of CB-NPs. In this study, a series of CB-NPs with different BLZ945/CA4 (B/C) ratios and drug loading contents were synthesized and evaluated on a hepatoma (H22) tumor-bearing mice model. The injection dose and B/C ratio were found to have a significant influence on the in vivo anticancer efficacy. The CB-NPs 20 with B/C weight ratio of 0.45/1, and total drug loading content (B + C) of 20.7 wt%, showed the highest potential for clinical application. Systematic pharmacokinetics, biodistribution, and in vivo efficacy evaluation for CB-NPs 20 have been finished, which may provide significant instruction for medicine screening and clinical application.
科研通智能强力驱动
Strongly Powered by AbleSci AI